Novo Nordisk shares retreat after ADA conference updates fail to excite investors (NVO)
chart down red arrow NEW SIZE ©Shutterstock Novo Nordisk (NYSE:NVO) shares fell 3% on Monday as investors digested…
Machine Learning Model Accurately Predicts Long-Term Risk of Type 2 Diabetes
Study of Over Three Million Patients for Risk of Type 2 Diabetes Demonstrates Potential for More Advanced Approach…
First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control
Phase 2 Study Results Highlight Use of Once-Daily Injection for Weight Loss and Reduction in Insulin Use NEW…
The American Diabetes Association Debuts the 2026 Scientific Sessions, Driving the Future of Diabetes Care
Leading Experts to Reveal Groundbreaking Research, Innovative Technologies, and Transformative Approaches in Obesity, Early Detection, and Diabetes Treatment…
Novo Nordisk faces new GLP-1 rival as Eli Lilly’s triple agonist sets weight-loss record
Novo Nordisk faces new GLP-1 rival as Eli Lilly’s triple agonist sets weight-loss record Proactive uses images sourced…